Physician profile
Peter Eugene Miller
NPI 1881823821
$3,633.27
in general payments reported to CMS, 2019-2025
32 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $674 · 2021: $710 · 2022: $455 · 2023: $304 · 2024: $401 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $675.36 | 2021-2025 | Interstim, Gi Genius |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.04 | 2019-2024 | Xifaxan |
| Medtronic USA, INC. | $344.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.41 | 2020-2022 | |
| Covidien Lp | $232.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $227.58 | 2019-2022 | |
| Intuitive Surgical, INC. | $199.52 | 2019-2022 | |
| Ethicon US, LLC | $190.12 | 2021-2023 | Echelon Flex |
| Braintree Laboratories, INC. | $172.28 | 2019-2024 | Suflave, Sutab |
| Axonics, INC. | $103.60 | 2020 | |
| La Jolla Pharmaceutical Company | $72.39 | 2021-2023 | Xerava |
| Monaghan Medical Corporation | $68.37 | 2024 | Aerochamber |
| Dilon Technologies, INC. | $62.50 | 2025 | Hemoblast Bellows |
| Integra Lifesciences Corporation | $58.76 | 2020-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boston Scientific Corporation | $50.02 | 2024-2025 | Watchman Flx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Northgate Technologies, INC. | $49.46 | 2024 | Stimsite |
| Pacira Pharmaceuticals Incorporated | $48.51 | 2021-2025 | Exparel |
| Mallinckrodt Hospital Products INC. | $43.36 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $40.77 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $39.02 | 2025 | |
| Napo Pharmaceuticals INC | $36.04 | 2023 | Mytesi |
| Baudax Bio INC. | $34.75 | 2020-2021 | |
| Shire North American Group INC | $30.49 | 2019 | |
| Mimedx Group, INC. | $30.48 | 2024 | |
| Davol INC. | $27.33 | 2021 | |
| Innovation Technologies INC | $24.99 | 2024 | Irrisept |
| Stryker Corporation | $24.09 | 2024 | N/A |
| Trevena, INC. | $15.63 | 2021 | |
| Bridgebio Pharma, INC. | $15.14 | 2025 | Attruby |
| Vioptix INC | $15.01 | 2021 | |
| Palette Life Sciences, INC. | $12.44 | 2022 | |
| Thd America, INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.